Growth hormone (GH) is important in maternal adaptation to pregnancy, and maternal circulating GH concentrations are reduced in human growth-restricted pregnancies. In the pig, maternal GH treatment throughout early to mid pregnancy increases fetal growth, despite constraining effects of adolescent and primiparous pregnancy, high litter size, and restricted maternal nutrition. Because GH cannot cross the placenta and does not increase placental weight, we hypothesized that its effects on fetal growth might be via improved placental structure or function. We therefore investigated effects of maternal GH treatment in pigs on structural correlates of placental function and placental expression of nutrient transporters important to fetal growth. Multiparous (sows) and primiparous pregnant pigs (gilts) were treated with GH (;15 lg kg À1 day À1 ) or vehicle from Days 25-50 of gestation (n ¼ 7-8 per group, term ;115 days). Placentas were collected at Day 50 of gestation, and we measured structural correlates of function and expression of SLC2A1 (previously known as GLUT1) and SLC38A2 (previously known as SNAT2) nutrient transporters. Maternal GH treatment did not alter placental size or structure, increased protein expression of SLC2A1 in trophoblast (+35% %; P ¼ 0.037) and on its basal membrane (+44% %; P ¼ 0.011), and increased SLC38A2 protein expression in the basal (+44% %; P ¼ 0.001) but not the apical cytoplasm of trophoblast. Our findings suggest that maternal GH treatment increases fetal growth, in part, by enhancing placental nutrient transporter protein expression and hence fetal nutrient supply as well as trophoblast proliferation and differentiation and may have the potential to ameliorate intrauterine growth restriction. growth hormone, nutrient transport, pig, placenta, trophoblast
INTRODUCTION
Growth hormone (GH) is important in maternal adaptation to pregnancy, with reduced maternal circulating GH in human growth-restricted pregnancies [1] . In the pig, maternal GH treatment during early to mid pregnancy increases fetal growth [2] [3] [4] [5] , muscle fiber number [6] , and plasma glucose [7] , and increases birth weight if continued until late gestation [3, 5, 8] . Intrauterine growth restriction (IUGR) is common in pigs, because fetal weight and birth size are constrained by adolescent pregnancy [2, 9] , limited uterine capacity, and large litter size [9, 10] , and by the restricted maternal nutrition regimen used in the pork industry [11, 12] . Low birth weight decreases postnatal survival and growth in pigs as in other species [10, [13] [14] [15] , and maternal GH treatment therefore has the potential to improve these outcomes.
Because GH and insulin-like growth factor 1 (IGF1) cannot cross the placenta [16, 17] , increases in fetal growth in response to maternal GH treatment must be due to changes in maternal metabolism, including increased circulating amino acids and glucose [3, 7] , and/or to improved placental function. Placental size was increased in pigs after maternal GH treatment in early to mid pregnancy with ;33 lg kg À1 d À1 , but not following lower doses of ;15 lg kg À1 d À1 [2, 4, 5] . In sheep, maternal GH treatment increases simple diffusion across the placenta [18] , increases fetal growth in normal pregnancy [19] , partially rescues the intrauterine growth-restricted phenotype after placental embolization [20] , and increases placental growth and the transplacental glucose gradient in intrauterine growth-restricted pregnancies induced by overnourishing adolescent dams [21] . These data suggest that maternal GH treatment can increase placental function and fetal growth, even with reduced placental blood flow. However, effects of maternal GH on placental structure are unknown.
Because GH increases maternal circulating concentrations of IGF1 in pigs [2, 4, 5, 7] , increased fetal growth may be due to effects of elevated GH or IGF1. Growth hormone receptors are present on the maternal uterine luminal epithelium throughout early and mid pregnancy in pigs, but whether they are also present in the fetal placenta is unknown [22] . The IGF1 receptor (IGF1R) is expressed on the maternal uterine luminal epithelium but not trophoblast at Day 20 of pregnancy in pigs, but its localization later in pregnancy has not been reported [23] . In pregnant guinea pigs, maternal IGF1 infusion increases late gestation placental uptake and transfer of glucose and amino acids, and the latter may be due to increased placental gene expression of Slc38a2 [24, 25] .
In pigs, as in other species, birth and placental weight are positively related [9] . Placental function can also increase independently of weight, through changes in structural and other determinants of nutrient transport. The pig has a noninvasive, diffuse placenta, and nutrient transport occurs across three maternal and three fetal layers ( Fig. 1 in Friess et al. [26] ). Specialist exchange areas, called areolae, also form in fetal placenta opposite the openings of uterine glands (Fig. 1) . Areloae are important for absorption of uterine secretions (histotroph) and form up to 10% of the surface area by midgestation [27] . Reduction of placental layer thickness throughout gestation is believed to increase placental efficiency to meet increasing fetal demand [26] . Placental nutrient transport is also determined by expression and activity of nutrient transporters. In rats, placental protein expression of solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1, previously known as GLUT1) is reduced in IUGR because of restricted uterine blood flow [28] , and inhibition of placental solute carrier family 38, member 2 (SLC38A2, previously known as SNAT2) activity reduces fetal weight [29] . Placentas of macrosomic infants from diabetic women have increased SLC2A1 expression in basal syncytiotrophoblast membrane [30, 31] . Placentas from IUGR babies have decreased system A activity in the syncytiotrophoblast microvillous membrane [32] . Within mouse litters, placental expression of SLC38A2 is highest in the fastest-growing fetuses [33] . Maternal growth hormone treatment in overnourished adolescent ewes, which induces IUGR in their fetuses, increases the transplacental glucose gradient but does not alter whole placentome expression of the genes encoding SLC2A1 or SLC2A3 [21] . These suggest that both SLC2A1 and SLC38A2 are important regulators of fetal growth, but the effects of maternal GH treatment on transporter activity or expression in the pig placenta are unknown.
Given these effects of maternal GH or IGF1 treatment, we hypothesize that injection of GH to pregnant sows and gilts during early to mid pregnancy increases fetal growth by enhancing placental structural differentiation and/or by increasing placental protein expression of the nutrient transporters SLC2A1 and SLC38A2.
MATERIALS AND METHODS

Animals and Tissue Collection
This study was approved by the University of Adelaide Animal Ethics Committee and performed in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. As described previously [2] , multiparous (sows) and primiparous (gilts) pregnant pigs were randomly allocated to treatment groups (control and GH treated), n ¼ 8 dams per group at Day 23 after mating. One GH-treated gilt was excluded from the study because it was not pregnant. All pigs were slaughtered at Day 50 of gestation (term ;115 days). Another gilt in the control group was excluded because it had only a single fetus. Chorionic sacs were detached from the endometrium and fetuses, and their placentas were weighed. Placentas were laid out flat on a 1-cm grid and digitally photographed for the measurement of placental area using VideoPro software (Leading Edge, Adelaide, Australia). Two samples distal to the uterine cord (;1.5 3 1 cm) were collected from each fetal placenta, fixed in 4% paraformaldehyde, processed, and paraffin embedded perpendicular to the surface.
Histology
Placental samples from the median-weight fetus for its litter and the fetus of the opposite sex closest in weight to the litter median were selected for the present study. Placental blocks were sectioned at 6 lm, every fifth slide was stained with Masson trichrome, and images were digitally captured using a 403 lens (NanoZoomer; Hamamatsu Co., Shizouka, Japan). For sections where the trophoblast was torn, the second distal sample was sectioned and stained.
Immunohistochemical Labeling of Blood Vessels and Nutrient Transporters
Two slides were selected adjacent to the Masson trichrome slides from each placenta (blood vessel density) or from that of the median-weight fetus only (nutrient transporter expression). IGF1R expression was localized in one placenta of a median-weight fetus from each treatment and parity combination. After dewaxing, antigen retrieval was performed with 0.03% pronase (SigmaAldrich, St. Louis, MO) at 378C for 10 min. Endogenous peroxidase activity and nonspecific staining were blocked by incubation in 6% H 2 O 2 (Ajax Finechem, Taren Point, Australia) and then 10% goat serum (IMVS, Adelaide, Australia) in antibody diluent, respectively. Sections were then incubated with primary antibodies overnight at room temperature (Table 1) , or without primary antibody (negative controls). An additional negative control was included for TUNG ET AL. localization of the IGF1R (Fig. 2B ), and these samples were incubated in the presence of nonimmune rabbit serum, diluted 1:10 000. This was calculated from manufacturer's information as containing an immunoglobulin G concentration similar to that of the polyclonal antibody to the IGF1R when diluted 1:500. The antibody used against SLC2A1 has previously been validated for use in porcine placental tissue [34] , whereas an anti-human SLC38A2 antibody was selected on the basis of protein sequence homology between porcine and human SLC38A2. After washing, sections were incubated with biotinylated polyclonal goat a-rabbit secondary antibody (1:200; Dako, Glostrup, Denmark) for 40 min, then with streptavidin horseradish peroxidase (Rockland Immunochemicals, Inc., Gilbertsville, PA) for 30 min at room temperature. Antibody binding was visualized with diaminobenzidine (SigmaAldrich). All antibody dilutions were made in 13 PBS with 1% bovine serum albumin and 10% goat serum, and 3 3 3 min washes in 13 PBS were performed between each step. Slides were counterstained with hematoxylin (SigmaAldrich), dehydrated in 90% and absolute ethanol with a 3 3 5 min clearing step in Safsolv (Ajax Finechem), and mounted with DPX (Sigma-Aldrich) and images were digitally captured as described above.
Image Analysis
Placental structure. There was insufficient length of the trophoblast layer available for analysis in placentas from the median-weight fetus in one control gilt, and the opposite-sex fetus from each of one control sow and one GHtreated sow. One control gilt only had fetuses of a single sex. At least five regions each of 500 lm were analyzed. The number of trophodermal ridges and the fetal placenta thickness [35] were measured at 103 resolution, and trophoblast thickness for each trough (Supplemental Fig. S1 , available online at www.biolreprod.org) was measured at 403 resolution using Nanozoomer software (NDP view; Hamamatsu Co.). Trophoblast surface length [35] was measured at 203 resolution with VideoPro image analysis software (Supplemental Fig. S1 ). Folding index was calculated as trophoblast surface length divided by the region length.
Capillary density. At least three regions each 500 lm long were analyzed. The peritrophoblast area was defined as between 20 lm below the base of the trophoblast and the apical surface of the trophoblast (Supplemental Fig. S1 ). The volume density of capillaries in the selected area was quantified at 403 resolution using VideoPro by dividing the number of grid intercepts positive for von Willebrand factor (VWF) by the total points in the peritrophoblast region (mean, 773 total points counted; range, 470-1215 points; grid spacing, 6.85 lm; Supplemental Fig. S1 ).
Localization and expression of nutrient transporters. Ten trophoblast troughs from a single section from each placenta labeled with SLC2A1 or SLC38A2 were scored for expression of nutrient transporters. One placenta from a control sow and one from a GH-treated gilt were excluded because an insufficient number of troughs were available for analysis. SLC2A1 expression in trophoblast cells and the basal membrane of the trophoblast and SLC38A2 expression in apical and basal trophoblast cytoplasm were visually scored on a scale from 0 to 3 based on color intensity (negative ¼ 0, weak-positive ¼ 1, medium-positive ¼ 2, strong-positive ¼ 3).
Statistical Analysis
To eliminate bias, the researcher (E.T.) was blinded to the identification of experimental groups during analysis. The effects of maternal parity, treatment, sex, and their interaction on fetal and placental outcomes were analyzed by repeated-measures ANOVA, with littermates considered repeated measures of the dam, including sex as a within factor, treatment and parity as between factors, and litter size as a covariate. Effects of treatment, parity, and their interaction on nutrient transporter expression were analyzed by two-way ANOVA with litter size as a covariate. All statistical tests were performed using PASW v18.0 for Windows (SPSS Inc., Chicago, IL). Data are presented as mean 6 SEM unless otherwise indicated, and a P value of ,0.05 was considered statistically significant.
RESULTS
Fetal and Placental Size
Fetal weight was increased by maternal GH treatment (þ9%; P ¼ 0.018) but was not altered by parity, fetal sex, or litter size (Table 2 ) in these fetuses, consistent with analyses of all fetuses in each litter [2] . Placental area was not altered by maternal treatment, parity, fetal sex, or litter size (P . 0.1; Table 2 ). Placental weight was negatively related to litter size (P ¼ 0.017; Table 2 ) but not altered by maternal treatment, parity, or fetal sex (P . 0.1; Table 2 ). Fetal:placental weight ratio was positively related to litter size (P ¼ 0.008) and not 
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altered by maternal treatment, parity, or fetal sex (P . 0.1; Table 2 ).
Placental Structure
The density of trophodermal ridges, trophoblast thickness, and folding index, and the volume density of peritrophoblast blood vessels were not altered by maternal treatment, parity, fetal sex, or litter size (P . 0.1; Table 2 ). Fetal placenta thickness was negatively related to litter size (P ¼ 0.020), was greater in sows than gilts (P ¼ 0.004), and was not altered by maternal treatment and fetal sex (P . 0.1; Table 2 ).
Localization and Expression of IGF1R
The IGF1R was consistently highly expressed in trophoblast and was also present in endothelium of vessels within the fetal placenta ( Fig. 2A) . Use of nonimmune rabbit serum as a negative control confirmed the absence of substantial background staining (Fig. 2B ).
Localization and Expression of Placental Nutrient Transporters
SLC2A1 was expressed in the trophoblast, especially in the basal membrane (Fig. 3A) and was also weakly expressed in endothelial cells (Fig. 3B) . SLC38A2 was strongly expressed in the trophoblast, particularly in the basal cytoplasm, and in endothelial cells and amnion (Fig. 3C) . SLC38A2 was also strongly expressed in the apical cytoplasm of the trophoblast layer in placental areolae (Fig. 3D) .
Overall, SLC2A1 expression in the trophoblast was increased by maternal GH treatment (þ35%; P ¼ 0.037) and was not altered by parity or litter size (P . 0.1; Fig. 4A ). SLC2A1 expression in the basal trophoblast membrane was also increased by maternal GH treatment (þ44%; P ¼ 0.011) but was not altered by parity or litter size (P . 0.1; Fig. 4A ). SLC38A2 expression in the basal cytoplasm of the trophoblast was increased by maternal GH treatment (þ44%; P ¼ 0.001) but did not differ with parity or litter size (P . 0.1; Fig. 4B ). SLC38A2 expression in the apical cytoplasm of the trophoblast was not altered by maternal GH treatment, parity, or litter size (P . 0.1; Fig. 4B ). In subgroup analyses, maternal GH administration increased SLC2A1 expression in trophoblast (P ¼ 0.009) and basal membrane of trophoblast (P ¼ 0.028), and increased SLC38A2 expression in basal (P ¼ 0.005) and apical (P ¼ 0.026) trophoblast cytoplasm in sows, but not in gilts (P . 0.1 for each).
DISCUSSION
We have demonstrated for the first time in any species that maternal GH treatment during early to mid pregnancy increases placental protein expression of the facilitated glucose transporter SLC2A1 and the system A amino acid transporter SLC38A2 at midpregnancy. This was not accompanied by alterations in structural correlates of placental function. Increased SLC2A1 in the porcine placenta will likely mediate enhanced transport of glucose from mother to fetus, consistent with the increases in fetal plasma glucose and fetal growth in GH-treated pigs [2-5, 7, 8] . SLC38A2 is a unidirectional amino acid transporter that transports neutral amino acids, such as alanine and proline, into cells [36] , and it also functions as a sensor of amino acid availability that signals via mTOR to stimulate cell growth [37] . Increased abundance of SLC38A2 in trophoblast cytoplasm may therefore reflect increased amino acid abundance and stimulate trophoblast growth and differentiation, improving subsequent placental function and thereby fetal growth. Determining how maternal GH treatment affects the net amino acid flux from mother to placenta or placenta to fetus will require further investigations using labeled substrates and/or measurement of additional amino acid transporters. Growth hormone might also regulate expression of additional placentally expressed nutrient transporters, such as GLUT3, SNAT1, and SNAT4, although in sheep placental expression of Slc2a1 (the gene for GLUT3) is not altered by maternal GH treatment [21] . Placental SLC2A1 and SLC38A2 expression changes in parallel to fetal growth in response to environmental perturbations and between-litter variation in rodents, sheep, and humans [28, [30] [31] [32] [33] , and inhibition of system A activity reduces fetal growth in rats [29] . Our results are therefore also consistent with regulation of fetal growth by placental expression of these transporters, but they highlight the need to investigate regional changes in expression. a Data are estimated marginal means 6 SEM, adjusted to an average litter size of 10.3, for all fetuses in which placental structure was measured. Data from placentae of littermates were analyzed as repeated measures of the dam, with treatment (control or GH treated) and parity group (sow or gilt) as between factors, fetal sex as a within factor, and litter size as a covariate. NS indicates P . 0.1. b Fetal weight tended to approach significance for an interaction between parity and fetal sex (P ¼ 0.06) c Placental area (P ¼ 0.069) and average fetal placenta thickness (P ¼ 0.086) tended to approach significance for the three-way interaction between treatment, parity, and sex.
TUNG ET AL.
Increased placental nutrient transporter expression in response to maternal GH might reflect indirect effects via IGF1, rather than direct effects of GH. We localized IGF1R, the main receptor for IGF1, to porcine trophoblast as well as blood vessel endothelium in these fetal placentae, making direct action of IGF1 possible. Incubation of human placental villous fragments with GH did not alter glucose uptake and decreased system A activity [38] , whereas incubation of cultured human trophoblasts with IGF1 increased system A activity [39] . In guinea pigs, maternal IGF1 infusion from early to mid pregnancy increases fetal weight, placental and fetal uptake, and transfer of glucose and amino acid and placental gene expression of SLC38A2 but not SLC2A1 [24, 25] . Maternal GH treatment increases maternal circulating levels of IGF1 in pigs [2, 4, 5, 7, 40] , which might therefore mediate the increase in placental protein expression of SLC2A1 and SLC38A2. The greater increase in IGF1 in sows (þ224%) than in gilts (þ121%) reported previously by us [2] might also explain why transporter immunoreactivity increased in sows, but not in gilts, when effects of maternal GH treatment were tested separately in the two parities. Greater placental SLC2A1 up-regulation might also contribute to greater increases in progeny birth weight following longer-term GH treatment in sows than gilts [8] .
In the current study, SLC2A1 was localized to endothelial cells and trophoblast, especially in the basal membrane. SLC2A1 protein was quantified in the fetal placenta in pigs [34] , whereas a preliminary report identified Slc2a1 mRNA expression in the conceptus and uterine luminal epithelium in gilts [41] . However, the precise localization of SLC2A1 in the porcine placenta has not previously been reported. In the rat placenta, SLC2A1 is located on the plasma membranes of both layers of syncytiotrophoblast [42] . In the human placenta, SLC2A1 is located in syncytiotrophoblast, cytotrophoblast, and endothelial cells, and its expression is higher in the microvillous (maternal-facing) compared with the basal (fetal-facing) membrane [43] . Transport across the basal membrane is the rate-limiting step for transplacental glucose transport in humans [44] . SLC2A1 expression in the basal membrane increases ;50% during the second half of gestation [43] . The predominantly basal expression pattern of SLC2A1 protein in the porcine placenta may maximize glucose transport to the fetus by facilitating transport to adjacent fetal capillaries.
We found SLC38A2 expressed in trophoblast, predominantly basally, and endothelial cells and amnion of the porcine placenta. In humans, the maximal transport capacity of the system A transporter is much higher in the maternal-facing than the fetal-facing membrane [32] . SLC38A2 is expressed in the syncytiotrophoblast and fetal endothelium in human and rat placenta [32, 45, 46] but has not previously been localized in the porcine placenta. The pattern of SLC38A2 expression observed in the present study may reflect amino acid accumulation in trophoblast and signaling via the mTOR pathway [37] to increase trophoblast proliferation and differentiation. We also observed strong SLC38A2 expression in the apical surface of trophoblast in placental areolae, similar to the expression pattern in rat and human placentas [32] . Areolae face the openings of maternal endometrial glands and transport macromolecules from mother to fetus by absorbing the nutrient-rich uterine milk (histotrophe) secreted from endometrial glands [47] . However, we were unable to quantify SLC38A2 expression in the areolae because there were limited numbers in our samples.
Contrary to our hypothesis, maternal GH treatment did not alter structural correlates of placental function in our study. Our data are consistent with previous findings in pregnant guinea PLACENTAL RESPONSES TO MATERNAL GH pigs administered IGF1 in early to mid pregnancy, which increased glucose and amino acid transport without changes in placental structure [24] . Placental structure and weights at Day 50 of the 115-day gestation were also similar in placentae of male and female fetuses in the present study, although placentae of female fetuses were heavier than those of male fetuses in analyses of all littermates from this study [48] . This suggests that placental growth trajectories differ between sexes, because placental weight is heavier in males than females at Day 70 of gestation, although this difference is lost by Day 104 of gestation [49] . We did observe that placental structure differed between parities, with a greater fetal placental thickness observed in placentae from sows than in those from gilts. Placental volume at midgestation in humans and the volume density of fetal capillaries in rabbit placenta strongly predict fetal and birth weight [50, 51] . Because sows generally deliver bigger litters with heavier piglets [8] , we speculate that a thicker placenta in midgestation may reflect higher proliferation in all cell lineages, which may be the precursor to enhanced placental function as the placenta differentiates across gestation. Similarly, a thinner placenta in midgestation in the smallest compared with the largest fetus of pig litters has been suggested to limit their capacity for increases in placental folding, and thus the surface area for exchange in later pregnancy [35] .
We conclude that maternal GH treatment in pigs during early to mid pregnancy increases protein expression of placental SLC2A1 and SLC38A2 transporters but does not alter structural correlates of placental function in the fetal part of the porcine placenta. This suggests that increased fetal weight in response to maternal GH administration in pigs may be partly due to increased glucose transport from mother to fetus, whereas increased SLC38A2 in trophoblast may reflect accumulation of amino acids and activation of the mTOR signaling pathway to promote trophoblast proliferation and differentiation. Direct measurements of nutrient fluxes between mother, placenta, and fetus are needed to confirm these mechanisms. More broadly, our findings suggest that strategies to increase maternal circulating GH may promote placental function and fetal growth, even in an environment that restricts fetal growth.
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